- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00622466
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with paclitaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with paclitaxel and to how well it works in treating patients with metastatic breast cancer.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
OBJECTIVES:
Primary
- To evaluate the efficacy of sorafenib tosylate and paclitaxel by measuring tumor response, as defined by RECIST criteria, in patients with metastatic, HER2-negative breast cancer.
Secondary
- To evaluate time to disease progression in patients treated with this regimen.
- To evaluate six-month progression-free survival of patients treated with this regimen.
- To evaluate time to treatment failure in patients treated with this regimen.
- To evaluate clinical benefit rate (tumor response and stable disease) at 24 weeks in patients treated with this regimen.
- To evaluate duration of response in patients treated with this regimen.
- To evaluate the tolerability of this regimen in these patients.
- To examine the relationship of gene expression and tissue/serum protein markers, where available, related to response to therapy focusing on growth factor receptor pathways.
OUTLINE: This is a multicenter study.
Patients receive oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 4 weeks.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75390
- University of Texas Southwestern Medical Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically* confirmed breast cancer
Stage IV (metastatic) disease
- Radiographic evidence of metastases NOTE: *Histological confirmation of the actual metastasis is not required.
Measurable disease by RECIST criteria defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (i.e., physical examination, CT scan, MRI, or x-ray) or ≥ 10 mm by spiral CT scan
- No prior radiotherapy unless growth has been documented following radiotherapy
Primary tumor or metastatic tumor HER2-negative, defined as the following:
- Immunohistochemistry of 0 or 1+ OR the equivalent, if an automated quantitative assay is used
- HER2 fluorescent in situ hybridization (FISH) assay negative as defined by a HER2:chromosome 17 centromeric probe ratio < 1.8 (or < 2.2 if immunohistochemistry is less than 3+ or equivalent) OR equivalent values for negative FISH assays that do not normalize to chromosome 17
- Hormone-receptor positive (estrogen receptor-[ER] or progesterone receptor [PgR]-positive) disease or hormone receptor-negative (ER- or PgR-negative) disease
- Tumor block from initial breast cancer primary or a biopsy of a metastatic site must be available for correlative studies
- Brain metastases allowed provided the patient is stable after completion of treatment (i.e., surgery and/or radiotherapy), asymptomatic, and off steroids with 2 consecutive stable brain scans at least 4 weeks after radiotherapy
Exclusion criteria:
- Bone-only or other nonmeasurable-only disease
- Newly diagnosed brain metastases
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-1
- Life expectancy > 6 months
- Menopausal status not specified
- WBC ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- AST and ALT transaminases ≤ 2.5 times ULN (< 5 times ULN if liver involvement)
- Creatinine < 1.5 times ULN OR creatinine clearance > 60 mL/min
- INR < 1.5 OR PT/PTT normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to and during (women and men) and for at least 3 months after (men) study therapy
- Able to swallow and absorb oral medications
Exclusion criteria:
Active or uncontrolled medical illness (e.g., active infection > CTCAE grade 2), including any of the following:
- HIV or chronic hepatitis B or C
- Uncontrolled diabetes
- NYHA class II-IV uncompensated congestive heart failure
- Unstable angina (anginal symptoms at rest)
- New onset angina (i.e., began within the past 3 months)
- Coronary artery disease
- Myocardial infarction within the past 6 months
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Evidence of bleeding diathesis or coagulopathy
- Pulmonary hemorrhage/bleeding event > CTCAE grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event > CTCAE grade 3 within 4 weeks of first study drug
- Thrombotic or embolic events (i.e., cerebrovascular accident), including transient ischemic attacks within the past 6 months
- Hypertension that cannot be controlled with medication to ≤ 150/90 mm Hg
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib tosylate
- Prior invasive cancer other than breast cancer except nonmelanoma skin cancer
- Chronic nonhealing wound or ulcer
PRIOR CONCURRENT THERAPY:
- No more than 1 prior chemotherapy regimen for metastatic breast cancer (MBC)
At least 3 weeks since prior hormonal therapy for MBC or adjuvant or neoadjuvant chemotherapy
- More than 1 year since adjuvant paclitaxel
- At least 4 weeks since major thoracic, abdominal, or pelvic surgery and recovered
- At least 3 weeks since prior and no concurrent investigational drugs
- Concurrent bisphosphonates allowed
- Concurrent anticoagulation agents (i.e., warfarin or heparin) allowed
- No anticipated need for or concurrent radiotherapy
- No concurrent Hypericum perforatum (St. John wort) or rifampin (rifampicin)
- No other concurrent anti-neoplastic drugs
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Sorfenib + Paclitaxel
Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
|
The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
Muut nimet:
Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Time to Tumor Progression
Aikaikkuna: Time from first treatment to disease progression or death (up to 36 months)
|
Progression-free survival was defined as the time of treatment to the earliest date of documentation of disease progression or death due to any cause.
In the case of a participant started treatment.
Tenth month of progression-free rate of sorafenib and paclitaxel will be compared agains the null progression free rate of 32% using normal approximation test.
|
Time from first treatment to disease progression or death (up to 36 months)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Tumor Response Rate
Aikaikkuna: Up to 36 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT and MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
The confirmed response rate was estimated by the number of confirmed responses divided by the total number of participants randomized.
|
Up to 36 months
|
Six-month Progression-free Survival
Aikaikkuna: 6 months
|
The proportion of patients with progression-free survival at 6 months.
Progression-free is measured from Day-1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Sole Tumors (RECIST) v1.1, or death on study.
Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new leasions.
|
6 months
|
Time to Treatment Failure
Aikaikkuna: Up to 36 months
|
Number of patients experiencing treatment failure.
|
Up to 36 months
|
Clinical Benefit Rate (Tumor Response and Stable Disease) at 24 Weeks
Aikaikkuna: 24 weeks
|
Number of patients with either complete response (CR) or partial response (PR) as defined in Response Evaluation Criteria in Solid Tumors (for patients with measurable disease).
Complete Response: Disappearance of all target lesions, disappearance of all non-target lesions for at least 4 weeks.
Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.
|
24 weeks
|
Duration of Response
Aikaikkuna: Up to 36 months
|
Number weeks until disease progression measured from Day-1 of study drug administration to disease progression.
|
Up to 36 months
|
Tolerability of Sorafenib/Paclitaxel Regimen
Aikaikkuna: Up to 36 months
|
Number of patients without experiencing treatment-related adverse events.
|
Up to 36 months
|
Determine the Relationship of Gene Expression and Tissue/Serum Protein Markers, Where Available, Related to Response to Therapy Focusing on Growth Factor Receptor Pathways.
Aikaikkuna: Up to 36 months
|
Median values taken for all assays at baseline and relationship to response vs. no response will be made to identify predictive markers using methods to detect differential expression between two groups samples, including variants of the two-sample t-test, analysis of variance, F-test, and the Wilcoxon rank-sum test.
|
Up to 36 months
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Barbara B. Haley, MD, Simmons Cancer Center
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Ihosairaudet
- Neoplasmat
- Neoplasmat sivustoittain
- Rintojen sairaudet
- Rintojen kasvaimet
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Tubuliinimodulaattorit
- Antimitoottiset aineet
- Mitoosin modulaattorit
- Antineoplastiset aineet, fytogeeniset
- Proteiinikinaasin estäjät
- Paklitakseli
- Sorafenibi
Muut tutkimustunnusnumerot
- STU 082010-161
- ONYX-SCCC-112007-035
- CDR0000587470 (Rekisterin tunniste: PDQ (Physician Data Query))
- NCI-2011-02791 (Rekisterin tunniste: CTRP (Clinical Trials Reporting System))
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Rintasyöpä
-
Gangnam Severance HospitalRekrytointiHER2 Rikastettu alatyyppi Breast Cancer, Herzuma, PAM50 -tutkimusKorean tasavalta
-
Novartis PharmaceuticalsValmisMetastaattinen rintasyöpä (MBC) | Locally Advance Breast Cancer (LABC)Yhdistynyt kuningaskunta, Espanja
-
BioNTech SESeventh Framework ProgrammeValmisRintasyöpä (TNBC (Triple Negative Breast Cancer))Ruotsi, Saksa
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RekrytointiAnatomisen vaiheen II rintasyöpä AJCC v8 | Anatomisen vaiheen III rintasyöpä AJCC v8 | Varhaisen vaiheen rintasyöpä | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Yhdysvallat
-
Emory UniversityNational Cancer Institute (NCI)PeruutettuPrognostisen vaiheen IV rintasyöpä AJCC v8 | Metastaattinen pahanlaatuinen kasvain aivoissa | Metastaattinen rintasyöpä | Anatominen vaihe IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Fudan UniversityRekrytointiRintasyöpä | Rintojen kasvain | Rintojen kasvaimet | HER2-positiivinen rintasyöpä | Paikallisesti edennyt rintasyöpä | HER2-negatiivinen rintasyöpä | Hormonireseptoripositiivinen kasvain | Hormonireseptorinegatiivinen kasvain | Varhaisvaiheen rintasyöpä | Triple-negative Breast Cancer (TNBC)Kiina
-
NRG OncologyNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiAnatomisen vaiheen IV rintasyöpä AJCC v8 | Prognostisen vaiheen IV rintasyöpä AJCC v8 | Metastaattinen pahanlaatuinen kasvain luussa | Metastaattinen pahanlaatuinen kasvain imusolmukkeissa | Metastaattinen pahanlaatuinen kasvain maksassa | Metastaattinen rintasyöpä | Metastaattinen pahanlaatuinen kasvain... ja muut ehdotYhdysvallat, Kanada, Saudi-Arabia, Korean tasavalta
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... ja muut yhteistyökumppanitAktiivinen, ei rekrytointiHormonireseptori positiivinen | Vaiheen IA rintasyöpä AJCC v7 | Vaiheen IB rintasyöpä AJCC v7 | Stage IIA Breast Cancer AJCC v6 ja v7 | Vaiheen IIB rintasyöpä AJCC v6 ja v7 | Vaiheen IIIB rintasyöpä AJCC v7 | Rintojen adenokarsinoomaYhdysvallat, Kanada, Australia, Puerto Rico, Uusi Seelanti, Irlanti, Peru, Yhdistynyt kuningaskunta
Kliiniset tutkimukset paclitaxel
-
Qilu Hospital of Shandong UniversityRekrytointiPitkälle edennyt mahalaukun tai gastroesofageaalisen liitoksen adenokarsinoomaKiina
-
University of Southern CaliforniaCTI BioPharma; ASCEND TherapeuticsValmisPitkälle edennyt paksusuolen syöpäYhdysvallat
-
Cook Group IncorporatedValmisPerifeerinen valtimotauti (PAD)Saksa, Uusi Seelanti
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's HospitalValmisRintasyöpä | Metastaattinen rintasyöpäYhdysvallat
-
Achieve Life SciencesValmis
-
Fudan UniversityRekrytointiKurkunpään syöpä | Kurkunpään kasvaimet | Hypofarynx-syöpäKiina
-
Deutsches Herzzentrum MuenchenBiotronik AGValmisAkuutti sepelvaltimo-oireyhtymä | Stabiili angina pectoris | RestenoosiSaksa
-
Provascular GmbHWilliam Cook EuropeValmisÄäreisvaltimotautiBelgia, Saksa
-
Hemoteq AGValmisSepelvaltimotauti | Sepelvaltimon arterioskleroosi | Sepelvaltimon ateroskleroosi | Sepelvaltimon restenoosiSaksa, Ranska
-
The Methodist Hospital Research InstituteCellular TherapeuticsValmis